Arqule Inc (ARQL) 1.50 $ARQL
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:58PM CDT
ArQule (ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share.
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
ArQule Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 6:00AM CDT
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the first quarter of 2014.
ArQule to Report First Quarter 2014 Financial Results on May 7, 2014
Business Wire - Wed Apr 30, 7:30AM CDT
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the first quarter of 2014 on Wednesday, May 7, 2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.
ArQule, Inc. to Present at Needham 13th Annual Healthcare Conference
Business Wire - Wed Apr 02, 7:30AM CDT
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Needham 13th Annual Healthcare Conference on Wednesday, April 9, 2014 at 11:20 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
Paolo Pucci of ArQule Inc. (ARQL)-Nasdaq bought Shares of ARQL
M2 - Mon Mar 17, 10:08AM CDT
Reported by InsiderCow.com at 2014-03-14 11:51:31 ET
ArQule's Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 12:37PM CST
ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
ArQule Reports Fiscal 2013 Year End and Fourth Quarter Results
Business Wire - Wed Mar 05, 6:00AM CST
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the year and for the fourth quarter ended December 31, 2013.
ArQule to Report Fiscal 2013 Financial Results on March 5, 2014
Business Wire - Wed Feb 26, 7:30AM CST
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2013 year-end and fourth quarter on Wednesday, March 5, 2014 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to discuss these results.
ArQule, Inc. to Present at RBC Capital Markets Healthcare Conference
Business Wire - Tue Feb 18, 7:30AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2014 RBC Capital Markets Healthcare Conference on Tuesday, February 25, 2014 at 10:30 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
Germ Cell Tumors - Pipeline Review, H2 2013
M2 - Mon Feb 17, 3:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/3t5hzv/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2013" report to their offering. 'Germ Cell Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Scope - A snapshot of the global therapeutic scenario for Germ Cell Tumors. - A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Germ Cell Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Germ Cell Tumors Overview Therapeutics Development Pipeline Products for Germ Cell Tumors - Overview Pipeline Products for Germ Cell Tumors - Comparative Analysis Germ Cell Tumors - Therapeutics under Development by Companies Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes Germ Cell Tumors - Pipeline Products Glance Clinical Stage Products Early Stage Products Germ Cell Tumors - Products under Development by Companies Germ Cell Tumors - Products under Investigation by Universities/Institutes Germ Cell Tumors - Companies Involved in Therapeutics Development Germ Cell Tumors - Therapeutics Assessment Drug Profiles alvocidib hydrocholride - Drug Profile palifosfamide - Drug Profile tivantinib - Drug Profile Allogeneic Tumor Cell Vaccine [celecoxib] [cyclophosphamide] - Drug Profile Combretastatin Analogs - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix Companies Mentioned ZIOPHARM Oncology, Inc. ArQule, Inc. Tolero Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ell_tumors About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Data on ArQule's Tivantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 4:40PM CST
ArQule recently announced that its partner Kyowa Hakko Kirin Co., Ltd. has initiated a phase III trial on tivantinib (ARQ 197) in Japan.
ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference
Business Wire - Wed Feb 05, 8:04AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014 at 8:25 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan
Business Wire - Tue Feb 04, 7:00AM CST
ArQule, Inc. (Nasdaq: ARQL) today reported the announcement by its partner, Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151) of the initiation of a Phase 3 clinical trial evaluating tivantinib (ARQ 197) in Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy.
Stock to Watch: Arqule Down 5.7% (ARQL)
Comtex SmarTrend(R) - Mon Feb 03, 11:42AM CST
Arqule (NASDAQ:ARQL) is one of today's worst performing low-priced stocks, down 5.7% to $2.16 on 1.1x average daily volume. Arqule has traded 568,000 shares thus far today, vs. average volume of 539,000 shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -1.4%) and underperformed the S&P 500 (-5.7% to the S&P's -1.5%) during today's trading.
ArQule (ARQL) Jumps: Stock Rises 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:18AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
This Week in Biotech: Clinical Trials and Tribulations
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 18, 12:17PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
ArQule Up on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 5:04PM CST
Shares of ArQule, Inc, (ARQL) were up 37.71% on data from two phase III trials: METIV-HCC and ATTENTION.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 17, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Stock to Watch: Arqule Up 15.3% (ARQL)
Comtex SmarTrend(R) - Fri Jan 17, 10:11AM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 15.3% to $2.72 on 6.3x average daily volume. Arqule has traded 2.6 million shares thus far today, vs. average volume of 406,000 shares per day. The stock has outperformed the Dow (15.3% to the Dow's 0.3%) and outperformed the S&P 500 (15.3% to the S&P's -0.1%) during today's trading.
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:58PM CDT
ArQule (ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share.
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
ArQule Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 6:00AM CDT
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the first quarter of 2014.
ArQule to Report First Quarter 2014 Financial Results on May 7, 2014
Business Wire - Wed Apr 30, 7:30AM CDT
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the first quarter of 2014 on Wednesday, May 7, 2014 at 7:00 a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern Time that day to discuss these results.
ArQule, Inc. to Present at Needham 13th Annual Healthcare Conference
Business Wire - Wed Apr 02, 7:30AM CDT
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Needham 13th Annual Healthcare Conference on Wednesday, April 9, 2014 at 11:20 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
Paolo Pucci of ArQule Inc. (ARQL)-Nasdaq bought Shares of ARQL
M2 - Mon Mar 17, 10:08AM CDT
Reported by InsiderCow.com at 2014-03-14 11:51:31 ET
ArQule's Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 12:37PM CST
ArQule reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
ArQule Reports Fiscal 2013 Year End and Fourth Quarter Results
Business Wire - Wed Mar 05, 6:00AM CST
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the year and for the fourth quarter ended December 31, 2013.
ArQule to Report Fiscal 2013 Financial Results on March 5, 2014
Business Wire - Wed Feb 26, 7:30AM CST
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the fiscal 2013 year-end and fourth quarter on Wednesday, March 5, 2014 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to discuss these results.
ArQule, Inc. to Present at RBC Capital Markets Healthcare Conference
Business Wire - Tue Feb 18, 7:30AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2014 RBC Capital Markets Healthcare Conference on Tuesday, February 25, 2014 at 10:30 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
Germ Cell Tumors - Pipeline Review, H2 2013
M2 - Mon Feb 17, 3:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/3t5hzv/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2013" report to their offering. 'Germ Cell Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Scope - A snapshot of the global therapeutic scenario for Germ Cell Tumors. - A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Germ Cell Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Germ Cell Tumors Overview Therapeutics Development Pipeline Products for Germ Cell Tumors - Overview Pipeline Products for Germ Cell Tumors - Comparative Analysis Germ Cell Tumors - Therapeutics under Development by Companies Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes Germ Cell Tumors - Pipeline Products Glance Clinical Stage Products Early Stage Products Germ Cell Tumors - Products under Development by Companies Germ Cell Tumors - Products under Investigation by Universities/Institutes Germ Cell Tumors - Companies Involved in Therapeutics Development Germ Cell Tumors - Therapeutics Assessment Drug Profiles alvocidib hydrocholride - Drug Profile palifosfamide - Drug Profile tivantinib - Drug Profile Allogeneic Tumor Cell Vaccine [celecoxib] [cyclophosphamide] - Drug Profile Combretastatin Analogs - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix Companies Mentioned ZIOPHARM Oncology, Inc. ArQule, Inc. Tolero Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ell_tumors About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Data on ArQule's Tivantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 4:40PM CST
ArQule recently announced that its partner Kyowa Hakko Kirin Co., Ltd. has initiated a phase III trial on tivantinib (ARQ 197) in Japan.
ArQule, Inc. to Present at Leerink Swann Global Healthcare Conference
Business Wire - Wed Feb 05, 8:04AM CST
ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Leerink Swann Global Healthcare Conference on Wednesday, February 12, 2014 at 8:25 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.
ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko Kirin in Japan
Business Wire - Tue Feb 04, 7:00AM CST
ArQule, Inc. (Nasdaq: ARQL) today reported the announcement by its partner, Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151) of the initiation of a Phase 3 clinical trial evaluating tivantinib (ARQ 197) in Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy.
Stock to Watch: Arqule Down 5.7% (ARQL)
Comtex SmarTrend(R) - Mon Feb 03, 11:42AM CST
Arqule (NASDAQ:ARQL) is one of today's worst performing low-priced stocks, down 5.7% to $2.16 on 1.1x average daily volume. Arqule has traded 568,000 shares thus far today, vs. average volume of 539,000 shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -1.4%) and underperformed the S&P 500 (-5.7% to the S&P's -1.5%) during today's trading.
ArQule (ARQL) Jumps: Stock Rises 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:18AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise by roughly 7% on the day.
This Week in Biotech: Clinical Trials and Tribulations
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 18, 12:17PM CST
With the SPDR S&P Biotech Index up 64% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
ArQule Up on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 5:04PM CST
Shares of ArQule, Inc, (ARQL) were up 37.71% on data from two phase III trials: METIV-HCC and ATTENTION.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 17, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Stock to Watch: Arqule Up 15.3% (ARQL)
Comtex SmarTrend(R) - Fri Jan 17, 10:11AM CST
Arqule (NASDAQ:ARQL) is one of today's best performing low-priced stocks, up 15.3% to $2.72 on 6.3x average daily volume. Arqule has traded 2.6 million shares thus far today, vs. average volume of 406,000 shares per day. The stock has outperformed the Dow (15.3% to the Dow's 0.3%) and outperformed the S&P 500 (15.3% to the S&P's -0.1%) during today's trading.
